Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

BioAge Labs (BIOA) Receivables - Net (2025 - 2026)

BioAge Labs' Receivables - Net history spans 1 years, with the latest figure at $769000.0 for Q4 2025.

  • On a quarterly basis, Receivables - Net changed N/A to $769000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $769000.0, a N/A change, with the full-year FY2025 number at $769000.0, changed N/A from a year prior.
  • Receivables - Net hit $769000.0 in Q4 2025 for BioAge Labs, up from $515000.0 in the prior quarter.
  • Over the last five years, Receivables - Net for BIOA hit a ceiling of $769000.0 in Q4 2025 and a floor of $361000.0 in Q1 2025.